Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

Clinical Cancer Research 13, 2023-2029, April 1, 2007. doi: 10.1158/1078-0432.CCR-06-2701
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shaffer, D. R.
Right arrow Articles by Scher, H. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shaffer, D. R.
Right arrow Articles by Scher, H. I.

Imaging, Diagnosis, Prognosis

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

David R. Shaffer1,9, Margaret A. Leversha2, Daniel C. Danila1,9, Oscar Lin3, Rita Gonzalez-Espinoza4, Bin Gu4, Aseem Anand4, Katherine Smith5, Peter Maslak5, Gerald V. Doyle6, Leon W.M.M. Terstappen6, Hans Lilja7, Glenn Heller8, Martin Fleisher4 and Howard I. Scher1,9

Authors' Affiliations: 1 Genitourinary Oncology Service, Department of Medicine, 2 Molecular Cytogenetics Core Laboratory, Departments of 3 Pathology and 4 Clinical Laboratories, 5 Leukemia Service, Department of Medicine, 6 Immunicon Corporation, Huntingdon Valley, Pennsylvania, 7 Urology Service, Department of Surgery, and 8 Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, and 9 Department of Medicine, Joan and Sanford E. Weill College of Medicine of Cornell University, New York, New York

Requests for reprints: Howard I. Scher, Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 646-422-4323; Fax: 212-988-0851; E-mail: Scherh{at}mskcc.org or Martin Fleisher, Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. E-mail: Fleishem{at}mskcc.org.

Purpose: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based assays that provide expression information on a consistent basis in real time with minimal patient discomfort. We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer.

Experimental Design: Blood was collected from 63 patients with metastatic prostate cancer. CTCs were isolated by the Cell Search system, which uses antibodies to epithelial cell adhesion marker and immunomagnetic capture. CTCs were defined as nucleated cells positive for cytokeratins and negative for CD45. Captured cells were analyzed by immunofluorescence, Papanicolau staining, and fluorescence in situ hybridization.

Results: Most patients (65%) had 5 or more CTCs per 7.5 mL blood sample. Cell counts were consistent between laboratories (c = 0.99) and did not change significantly over 72 or 96 h of storage before processing (c = 0.99). Their identity as prostate cancer cells was confirmed by conventional cytologic analysis. Molecular profiling, including analysis of epidermal growth factor receptor (EGFR) expression, chromosome ploidy, and androgen receptor (AR) gene amplification, was possible for all prostate cancer patients with ≥5 CTCs.

Conclusions: The analysis of cancer-related alterations at the DNA and protein level from CTCs is feasible in a hospital-based clinical laboratory. The alterations observed in EGFR and AR suggest that the methodology may have a role in clinical decision making.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
D. C. Danila, G. Heller, G. A. Gignac, R. Gonzalez-Espinoza, A. Anand, E. Tanaka, H. Lilja, L. Schwartz, S. Larson, M. Fleisher, et al.
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Clin. Cancer Res., December 1, 2007; 13(23): 7053 - 7058.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. de Bono, G. Attard, A. Adjei, M. N. Pollak, P. C. Fong, P. Haluska, L. Roberts, C. Melvin, M. Repollet, D. Chianese, et al.
Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
Clin. Cancer Res., June 15, 2007; 13(12): 3611 - 3616.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2007 by the American Association for Cancer Research.